In September 2006, the Analytical Proteomics Team from Purdue and Indiana universities was selected by the National Cancer Institute (NCI) as one of five national centers to assess cancer biomarker proteomics technologies. The APT, along with Broad Institute of MIT and Harvard, University of California at San Francisco Lawrence Berkeley National Laboratory, Memorial Sloan-Kettering Cancer Center, and Vanderbilt University School of Medicine formed the Clinical Proteomics Technology Assessment for Cancer (CPTAC) network. The CPTAC program is a five-year, $104 million NCI initiative to create a foundation of technologies, data, reagents and standards, analysis systems, and infrastructure for the discovery and validation of clinically relevant cancer biomarkers. The consortium is focused on systematically advancing understanding of protein biology in cancer, and accelerating discovery research and clinical applications. register to read more...